Accera Completes Enrollment in Alzheimer’s Disease Treatment Phase 3 Clinical Trial

Accera Completes Enrollment in Alzheimer’s Disease Treatment Phase 3 Clinical Trial
Boulder, Colorado-based Accera has completed enrollment for its Phase 3 NOURISH AD clinical trial of AC-1204 for the treatment of mild to moderate Alzheimer's disease (AD). Top-line data should be reported later this year. AC-1204 is an orally administered therapy with the potential to improve dementia patients’ cognition and daily functioning. The treatment works by inducing a mild state of ketosis, thereby providing an alternative energy source to the brain. AC-1204 potentially has a number of favorable properties as a product candidate for dementia, including once-daily dosing, a low potential for drug interactions, and a long history of safe use. NOURISH AD is a 26-week, double-blind, randomized, placebo-controlled, parallel-group Phase 3 clinical trial to investigate the effects of daily administration of AC-1204 in participants with mild to moderate AD with an optional 26-week open label extension. The primary and secondary endpoints will assess the effect of AC-1204 in the cognition and memory as measured by the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the effects of the drug on patients' global function as measured by the Alzheimer's Disease Study Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC). Data from this trial will inform the design of a second pivotal Phase 3 trial, compulsory for regulatory approval of the drug, which Accera is planning to start early next year. "Accera is one of a few companies that will report Phase 3 clinical results in Alzheimer's in 2016," Dr. Charles Stacey, the compan
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *